Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice

Rheumatology

Volumn 46, Issue 7, 2007, Pages 1191-1199

  Bombardieri, S ^a   Ruiz, A A ^b   Fardellone, P ^c   Geusens, P ^d   McKenna, F ^e   Unnebrink, K ^f   Oezer, U ^f   Kary, S ^f   Kupper, H ^f   Burmester, G R ^g  

^a UNIVERSITY OF PISA   (Italy)

^b HOSPITAL DE CRUCES   (Spain)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d Belgium University Hospital   (Netherlands)

^e TRAFFORD GENERAL HOSPITAL   (United Kingdom)

^f ABBOTT GMBH AND CO KG   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adalimumab; Etanercept; Infliximab; Rheumatoid arthritis; TNF antagonist

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; LEFLUNOMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ANAPHYLAXIS; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INFECTION; INFECTION RISK; INJECTION SITE REACTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE REGRESSION; OPEN STUDY; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; HEALTH STATUS INDICATORS; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; REGRESSION ANALYSIS; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34447319146     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem091     Document Type: Article

References (45)

1. Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database Syst Rev 2005;CD005113.
2. Genovese MC, Bathon JM, Fleischmann RM et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol 2005;32:1232-42.
3. St. Clair EW, van der Heijde DM, Smolen JS et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
4. Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
5. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
6. van der Heijde D, Klareskog L, Rodriguez-Valverde V et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: 2-yr clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063-74.
7. Smolen JS, van der Heijde DM, St Clair EW et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial. Arthritis Rheum 2006;54:702-10.
8. Smolen JS, Han C, Bala M et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52:1020-30.
9. Lam J, Takeshita S, Barker JE, Kanigawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000;106:1481-8.
10. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: Findings of a consensus panel. Semin Arthritis Rheum 2005;34:819-36.
11. Gomez-Reino JJ, Carmona L. The BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a 4-yr period. Arthritis Res Ther 2006;8:R29, Published Online First: Doi:10.1186/ar1881.
12. Solau-Gervais E, Laxenaire N, Cortet B, Dubucquoi S, Duquesnoy B, Flipo RM. Lack of efficacy of a third tumour necrosis factor {alpha} antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology 2006;45:1121-4.
13. Nikas SN, Voulgari PV, Alamanos Y et al. Efficacy and safety of switching from infliximab to adalimumab: A comparative controlled study. Ann Rheum Dis 2006;65:257-60.
14. Bennett AN, Peterson P, Zain A, Grumley J, Panayi G, Kirkham B. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology 2005;44:1026-31.
15. van der Bijl AE, Breedveld FC, Antoni CE et al. Adalimumab (HUMIRA®) is effective in treating patients with rheumatoid arthritis who previously failed infliximab (absract SAT0062]. Ann Rheum Dis 2005;64(Suppl. III):428.
16. Wick MC, Emestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): Results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 2005;34:353-8.
17. Cohen G, Courvoisier N, Cohen JD, Zaltni S, Sany J, Combe B. The efficacy of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005;23:795-800.
18. Brocq O, Albert C, Roux C, Gerard D, Breuil V, Ziegler LE. Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy: experience with 18 patients. Joint Bone Spine 2004;71:601-3.
19. Haraoui B, Keystone EC, Thorne JC et al. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 2004;31:2356-9.
20. Hansen KE, Hildebrand JP, Genovese MC et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004;31:1098-102.
21. Gomez-Puerta JA, Sanmarti R, Rodriguez-Cros JR, Canete JD. Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy. Ann Rheum Dis 2004;63:896.
22. Sanmarti R, Gomez-Puerta JA, Rodriguez-Cros JR, Albaladejo C, Munoz-Gomez J, Canete JD. Etanercept in rheumatoid arthritis patients with a poor therapeutic response to infliximab. Med Clin (Barc) 2004;122:321-4.
23. Schwartzman S, Fleischmann R, Morgan GJ Jr. Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis? Arthritis Res Ther 2004;6(Suppl. 2):S3-S11.
24. Yazici Y, Erkan D. Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed? Ann Rheum Dis 2004;63:607-8.
25. Ang HT, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J Rheumatol 2003;30:2315-8.
26. van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: date from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann Rheum Dis 2003;62:1195-8.
27. van Vollenhoven RF. Switching between biological agents. Clin Exp Rheumatol 2004;22(5 Suppl. 35):S115-S21.
28. Brocq O, Plubel Y, Breuil V et al. Etanercept - infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNF alpha. Presse Med 2002;31(39 Pt 1):1836-9.
29. Burmester GR, Mariette X, Montecucco CM et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: The Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis Published Online First: 20 March 2007, doi:10.1136/ard.2006.066761.
30. Arnett FC, Edworthy SM, Bloch DA et al. American Rheumatism Association 1988 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31;315-24.
31. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
32. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organizationt/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
33. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
34. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: The Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
35. Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology 2004;43:1252-5.
36. Furst DE, Breedveld FC, Kalden JR et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis 2002;61(Suppl. 2):iI2-ii7.
37. Furst DE, Breedveld FC, Kalden JR et al. Updated consensus statement on biological agents, specifically tumour necrosis factor (alpha) (TNF(alpha)) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005;64(Suppl. 4):iV2-iv14.
38. Furst DE, Schiff MH, Fleischmann RM et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-71.
39. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003;48:35-45, Erratum in: Arthritis Rheum 2003;48:855; Arthritis Rheum 2004;22:144.
40. Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
41. van de Putte LB, Atkins C, Malaise M et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16.
42. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003;62(Suppl. 2):13-6.
43. Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23, Erratum in: N Engl J Med 2005;353:2311.
44. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
45. van der Laken CJ, Voskuyl AE, Roos JC et al. Imaging and serum analysis of immune complex formation of radiolabeled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 2007;66:253-6.